DBV Technologies annonce sa participation à plusieurs conférences investisseurs en septembre
Filed with Euronext · · 2 pages · French
Summary by 6ix AI
DBV Technologies announces its participation in several investor conferences in September. The company will attend the Cantor Global Healthcare Conference on September ninth. DBV Technologies is a biopharmaceutical company focused on developing treatments for food allergies and other immunological conditions. The company is currently studying the use of its VIASKIN® patch technology for treating food allergies.
Written in English by 6ix AI from the company’s French-language filing. How 6ix writes summaries
Earlier from DBV Technologies
- Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 août 2026
- DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq
- DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales
- DBV Technologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Report
- DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update
Later from DBV Technologies
- DBV Technologies to Participate in Upcoming September Investor Conferences
- DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years
- DBV Technologies annonce le dépôt de sa demande de licence biologique (BLA) auprès de la Food and Drug Administration des Etats-Unis pour le patch VIASKIN® Peanut destiné aux enfants âgés de 4 à 7 ans.
- DBV Technologies to Report Third Quarter 2026 Financial Results and Business Update on October 28, 2026
- DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update
Follow DBV Technologies into a list and get an email when it puts out news.
Follow DBV Technologies